Latest Earnings Results: Q2 '26
Estimated EPS
-$1.69
Reported EPS
-$24.14
Surprise
-1328.4%
Estimated Rev
$3M
Reported Rev
$7.88M
Surprise
+162.57%
• Reported GAAP EPS of -$24.14 down -804.12% YoY • Reported revenue of $7.88M up 166.66% YoY • Cue Biopharma, Inc. believes that its cash and cash equivalents on hand as of June 30, 2026, along with the net proceeds from the July 2026 private placement, will be sufficient.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$1.35 | -- | -- | N/A |
Q2 '26 | -$1.69 | -$24.14 | -1328.40% | MISSED |
Q1 '26 | -- | -$1.08 | -- | N/A |
Q4 '25 | -$2.70 | $0.30 | 111.11% | BEAT |
Q3 '25 | -$0.09 | -$0.07 | 25.00% | BEAT |